Outcome of bimodality definitive chemoradiation does not differ from that of trimodality upfront neck dissection followed by adjuvant treatment for >6 cm lymph node (N3) head and neck cancer
Open Access
- 3 December 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (12) , e0225962
Abstract
Currently, data regarding optimal treatment modality, response, and outcome specifically for N3 head and neck cancer are limited. This study aimed to compare the treatment outcomes between definitive chemoradiotherapy (CCRT) to the neck and upfront neck dissection followed by adjuvant CCRT. Ninety-three N3 squamous cell carcinoma head and neck cancer patients were included. Primary tumor treatment was divided to definitive CCRT (CCRT group) or curative surgery followed by adjuvant CCRT (surgery group). Neck treatment was also classified into two treatment modalities: definitive CCRT to the neck (CCRT group) or curative neck dissection followed by adjuvant CCRT (neck dissection group). Overall, the 2-year overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) were 51.8%, 47.3%, 45.6%, and 43.6%, respectively. In both oropharyngeal cancer and nonoropharyngeal cancer patients, in terms of OS, LRFS, RRFS or DMFS no difference was noted regarding primary tumor treatment (CCRT vs. surgery) or neck treatment (CCRT vs. neck dissection). In summary, N3 neck patients treated with definitive CCRT may achieve similar outcomes to those treated with upfront neck dissection followed by adjuvant CCRT. Caution should be made to avoid overtreatment for this group of patients.Keywords
All Related Versions
Funding Information
- National Taiwan University Hospital (NTUH 104-M2861, NTUH 105-N3224 and NTUH 106-N3609)
This publication has 20 references indexed in Scilit:
- Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer DatabaseHead & Neck, 2017
- PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck CancerNew England Journal of Medicine, 2016
- Matted nodes as a predictor of distant metastasis in advanced-stage III/IV oropharyngeal squamous cell carcinomaHead & Neck, 2014
- Outcomes after primary chemoradiotherapy for N3 (>6 cm) head and neck squamous cell carcinoma after an FDG‐PET‐‐guided neck management policyHead & Neck, 2013
- Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trialThe Lancet Oncology, 2013
- Outcomes of head and neck squamous cell carcinoma patients with N3 neck disease treated primarily with chemoradiation versus surgical resectionThe Laryngoscope, 2011
- Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trialThe Lancet Oncology, 2011
- Extensive Neck Node Metastases (N3) in Head and Neck Squamous CarcinomaOtolaryngology–Head and Neck Surgery, 2010
- Outcome With Neck Dissection After Chemoradiation for N3 Head-and-Neck Squamous Cell CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- N2‐N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders—Results of Trans Tasman Radiation Oncology Group Study 98.02Head & Neck, 2008